UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28, 2004
Commission File Number: 0-15360
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Oregon | | 93-1099680 |
(State or other jurisdiction of incorporation
or organization) | | (I.R.S. Employer Identification No.) |
| | |
211 Somerville Road, Route 202 North,
Bedminster, NJ | | 07921 |
(Address of principal executive offices) | | (Zip Code) |
| | |
Registrant’s telephone number, including area code: (908) 470-2800 |
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
1
Item 7. Financial Statements and Exhibits
(c) Exhibits
The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:
99.1 Press release dated April 28, 2004 regarding Bioject’s first quarter ended March 31, 2004 revenue and earnings.
Item 12. Results of Operations and Financial Condition
On April 28, 2004, Bioject announced a net loss of $1.5 million, or $0.12 per share, on revenue of $3.0 million for its first quarter of 2004 ended March 31, 2004.
A copy of the April 28, 2004 press release is included as exhibit 99.1 hereto. This exhibit is not filed, but is furnished pursuant to Item 12. (a) of Form 8-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 28, 2004 | BIOJECT MEDICAL TECHNOLOGIES INC. |
| (Registrant) |
| |
| |
| /s/ JAMES O’SHEA | |
| James O’Shea |
| Chairman of the Board, Chief Executive Officer
and President (Principal Executive Officer) |
| |
| |
| /s/ JOHN GANDOLFO | |
| John Gandolfo |
| Chief Financial Officer and Vice President of Finance
(Principal Financial and Accounting Officer) |
3
